Ticlopidine HCL是血小板凝集抑制剂,经主任教授J.Donald Easton博士研究证实它的重要作用是能替代阿司匹林用于预防和治疗大多数有可能发生梗塞危险的病人。新近的研究证明,Ticlopidine对发生梗塞症状先兆的病人能防止血栓形成,如短暂性局部缺血、短暂性单目失明,可逆的局部缺血 Ticlopidine HCL, a platelet aggregation inhibitor, has been shown to work as an alternative to aspirin for the prevention and treatment of the majority of patients at risk of developing infarction, according to a study by Dr. J. Donald Easton, a professor in charge of the study. Recent studies have shown that Ticlopidine can prevent thrombosis in patients with signs of infarction symptoms such as transient ischemia, transient unilateral blindness, reversible ischemia